SG11202007884UA - Saposin c pharmaceutical compositions and methods of treating cancer - Google Patents

Saposin c pharmaceutical compositions and methods of treating cancer

Info

Publication number
SG11202007884UA
SG11202007884UA SG11202007884UA SG11202007884UA SG11202007884UA SG 11202007884U A SG11202007884U A SG 11202007884UA SG 11202007884U A SG11202007884U A SG 11202007884UA SG 11202007884U A SG11202007884U A SG 11202007884UA SG 11202007884U A SG11202007884U A SG 11202007884UA
Authority
SG
Singapore
Prior art keywords
saposin
methods
pharmaceutical compositions
treating cancer
cancer
Prior art date
Application number
SG11202007884UA
Inventor
Ellen K Monson
Xiaochen Wei
Ray Takigiku
Cruze, Iii
Joseph W Wyse
Original Assignee
Bexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexion Pharmaceuticals Inc filed Critical Bexion Pharmaceuticals Inc
Publication of SG11202007884UA publication Critical patent/SG11202007884UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/40—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/20—Coumarin derivatives
    • C12Q2334/22—4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11202007884UA 2018-03-23 2018-11-02 Saposin c pharmaceutical compositions and methods of treating cancer SG11202007884UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647058P 2018-03-23 2018-03-23
US201862678668P 2018-05-31 2018-05-31
PCT/US2018/059016 WO2019182650A1 (en) 2018-03-23 2018-11-02 Saposin c pharmaceutical compositions and methods of treating cancer

Publications (1)

Publication Number Publication Date
SG11202007884UA true SG11202007884UA (en) 2020-09-29

Family

ID=64664378

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007884UA SG11202007884UA (en) 2018-03-23 2018-11-02 Saposin c pharmaceutical compositions and methods of treating cancer

Country Status (16)

Country Link
US (3) US10682411B2 (en)
EP (2) EP4005562A1 (en)
JP (3) JP7081865B2 (en)
KR (2) KR102370952B1 (en)
CN (2) CN111902133B (en)
AU (1) AU2018414543A1 (en)
BR (1) BR112020018334A2 (en)
CA (1) CA3094928A1 (en)
ES (1) ES2895180T3 (en)
IL (1) IL277313B (en)
MX (1) MX2020009829A (en)
PL (1) PL3768246T3 (en)
PT (1) PT3768246T (en)
RU (1) RU2767199C1 (en)
SG (1) SG11202007884UA (en)
WO (1) WO2019182650A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102370952B1 (en) * 2018-03-23 2022-03-07 벡션 파마슈티컬스 인크. Saposin C pharmaceutical composition and cancer treatment method

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
CN100366286C (en) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS: a novel anti-tumor agent
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP3357490A1 (en) 2006-04-28 2018-08-08 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and polypeptides for application to transmembrane drug delivery systems
CN101437485A (en) 2006-05-09 2009-05-20 高露洁-棕榄公司 Oral care regimen
BRPI0717475A2 (en) 2006-10-20 2014-03-11 Childrens Hosp Medical Center UNILAMELAR SPONTANEOUS PHILOSPHOLIPID UNILAMELAR VESICULES
CN101209251A (en) 2006-12-28 2008-07-02 中国科学院理化技术研究所 Elastic nano vesicle preparation containing paclitaxel or docetaxel and preparation method thereof
WO2009049422A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
BRPI0823234A2 (en) * 2008-11-07 2019-09-24 Childrens Hospital Med Ct nanovesicle for releasing an agent to a biological membrane and process for directing an agent to a cell membrane or tissue.
CN108926535B (en) 2011-02-01 2020-12-29 常州长吉生物技术开发有限公司 SapC-phospholipid nano vesicle freeze-dried preparation, preparation method and application thereof
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN104684546A (en) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 Nanotherapeutics for drug targeting
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
US10760112B2 (en) * 2014-12-18 2020-09-01 Shire Human Genetic Therapies, Inc. Enzymatic activity assays for glucocerebrosidase
CN108290894A (en) * 2015-07-01 2018-07-17 西北大学 Substituted 4- methyl-pyrrols simultaneously [1,2-A] pyrimidine -8- Carbox amides and its adjust glucocerebrosidase activity purposes
WO2018094406A1 (en) 2016-11-21 2018-05-24 Bexion Pharmaceuticals, Inc. A combination therapy including sapc-dops for the treatment of pancreatic cancer
KR102370952B1 (en) * 2018-03-23 2022-03-07 벡션 파마슈티컬스 인크. Saposin C pharmaceutical composition and cancer treatment method

Also Published As

Publication number Publication date
JP7313091B2 (en) 2023-07-24
PL3768246T3 (en) 2022-01-03
PT3768246T (en) 2021-09-07
EP3768246A1 (en) 2021-01-27
US11590227B2 (en) 2023-02-28
AU2018414543A1 (en) 2020-11-19
CA3094928A1 (en) 2019-09-26
WO2019182650A1 (en) 2019-09-26
KR102370952B1 (en) 2022-03-07
CN111902133B (en) 2022-04-15
JP2021518443A (en) 2021-08-02
KR20200136003A (en) 2020-12-04
BR112020018334A2 (en) 2021-02-17
US20200384112A1 (en) 2020-12-10
MX2020009829A (en) 2021-01-08
KR102483046B1 (en) 2022-12-29
JP7081865B2 (en) 2022-06-07
KR20220034916A (en) 2022-03-18
EP3768246B1 (en) 2021-08-25
CN114642720A (en) 2022-06-21
IL277313A (en) 2020-10-29
US20230226188A1 (en) 2023-07-20
ES2895180T3 (en) 2022-02-17
RU2767199C1 (en) 2022-03-16
JP2022110121A (en) 2022-07-28
CN111902133A (en) 2020-11-06
US10682411B2 (en) 2020-06-16
EP4005562A1 (en) 2022-06-01
IL277313B (en) 2021-05-31
JP2023118847A (en) 2023-08-25
US20190290764A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
IL263641A (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
EP3777888A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
EP3490581A4 (en) Neuromodulating compositions and related therapeutic methods for the treatment of cancer
EP3894392A4 (en) Compositions and methods for the treatment of cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL276808A (en) Compositions and methods for cancer treatment
EP4034138A4 (en) Compositions and methods for treatment of liquid cancers
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL269901B (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
IL254842A0 (en) Therapeutic compositions and methods of use for treating cancer
IL266486A (en) Pharmaceutical compositions and methods for the treatment of cancer
IL276203A (en) Compositions and methods of treating cancer
IL282251A (en) Compositions and methods for treatment of liver disease
ZA201808232B (en) Compositions and methods for the treatment of cancer
IL287538A (en) Compositions and methods for treatment of cancer
EP3468540A4 (en) Pharmaceutical compositions and methods for treatment of pain
IL265824A (en) Methods and pharmaceutical compositions for the treatment of kidney cancer
IL272147A (en) Methods and compositions for the treatment of cancer
IL277313B (en) Saposin c pharmaceutical compositions and methods of treating cancer
EP3817774A4 (en) Compositions and methods for local delivery of pharmaceutical agents to treat cancer
EP3681498A4 (en) Methods and compositions for the treatment of cancer
EP3525787A4 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
EP3515431A4 (en) Compositions and methods for treatment of cancer
IL280262A (en) Compositions and methods for the treatment of cancer
EP3730513C0 (en) Peptide and pharmaceutical compositions of same for use as an antimicrobial and in cancer treatment